ethyl 3-(4-bromophenyl)-3-hydroxypropanoate | 70200-16-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-(4-bromophenyl)-3-hydroxypropanoate
• 英文别名: (-)-ethyl 3-(4-bromophenyl)-3-hydroxypropionate
• CAS: 70200-16-7
• 化学式: C₁₁H₁₃BrO₃
• mdl: MFCD16749036
• 分子量: 273.126
• InChiKey: AMCGFHIZMJGGHD-UHFFFAOYSA-N

物化性质

• 沸点：
  366.7±27.0 °C(Predicted)
• 密度：
  1.439±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-(4-bromophenyl)-3-hydroxypropanoate 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以3.3 g的产率得到1-(4-溴苯基)-1,3-丙二醇
  参考文献：
  名称：

  Synthesis and Characterization of a Novel Liver-Targeted Prodrug of Cytosine-1-β-d-arabinofuranoside Monophosphate for the Treatment of Hepatocellular Carcinoma

  摘要：

  Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. These characteristics lead to poor efficacy, high toxicity, and a drug class associated with an unacceptable therapeutic index. Cyclic 1-aryl-1,3-propanyl phosphate prodrugs selectively release the monophosphate of a nucleoside (NMP) into CYP3A4-expressing cells, such as hepatocytes, while leaving the prodrug intact in plasma and extrahepatic tissues. This prodrug strategy was applied to the monophosphate of the well-known cytotoxic nucleoside cytosine-1-beta-D-arabinofuranoside (cytarabine, araC). Compound 19S (MB07133), in mice, achieves good liver targeting compared to araC, generating > 19-fold higher cytarabine triphosphate (araCTP) levels in the liver than levels of araC in the plasma and > 12-fold higher araCTP levels in the liver than in the bone marrow, representing a > 120-fold and > 28-fold improvement, respectively, over araC administration.

  DOI：

  10.1021/jm0607449
• 作为产物：
  描述：

  (4-溴苯甲酰)乙酸乙酯 在 水 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 联硼酸频那醇酯 作用下， 反应 10.0h， 以81%的产率得到ethyl 3-(4-bromophenyl)-3-hydroxypropanoate
  参考文献：
  名称：

  来自H 2 O的质子的无核化：通过B 2 pin 2 / H 2 O系统对羰基化合物的无金属化学选择性还原

  摘要：

  H 2 O通常被描述为质子供体，但是，在存在硼化合物的情况下，成功开发了H 2 O在无金属条件下的空泡反应，该反应可提供氢化物，从而实现高效且化学选择性的还原的C O债券。在酯，烯烃，卤素，硫醚，磺酰基，氰基以及杂芳族基团的存在下，该策略对羰基表现出优异的化学选择性。

  DOI：

  10.1039/c7ob00820a

文献信息

• Iron(0)-Mediated Reformatsky Reaction for the Synthesis of β-Hydroxyl Carbonyl Compounds
  作者：Xuan-Yu Liu、Xiang-Rui Li、Chen Zhang、Xue-Qiang Chu、Weidong Rao、Teck-Peng Loh、Zhi-Liang Shen

  DOI：10.1021/acs.orglett.9b01999

  日期：2019.8.2

  An efficient, economical, and practical Reformatsky reaction of α-halo carbonyl compounds with aldehydes/ketones by using cheap and commercial iron(0) powder as reaction mediator is developed. The reactions proceeded effectively in the presence of a catalytic amount of iodine (20 mol %) to afford the synthetically useful β-hydroxyl carbonyl compounds in moderate to good yields.

  通过使用廉价的市售铁（0）粉末作为反应介质，开发了α-卤代羰基化合物与醛/酮的高效，经济和实用的Reformatsky反应。该反应在催化量的碘（20mol％）的存在下有效地进行，以中等至良好的产率提供了合成上有用的β-羟基羰基化合物。
• One-pot enol silane formation-Mukaiyama aldol reactions: Crossed aldehyde-aldehyde coupling, thioester substrates, and reactions in ester solvents
  作者：C. Wade Downey、Grant J. Dixon、Jared A. Ingersoll、Claire N. Fuller、Kenneth W. MacCormac、Anna Takashima、Rohina Sediqui

  DOI：10.1016/j.tetlet.2019.151192

  日期：2019.10

  Trimethylsilyl trifluoromethanesulfonate (TMSOTf) and a trialkylamine base promote both in situ enol silane/silyl ketene acetal formation and Mukaiyama aldol addition reactions between a variety of reaction partners in a single reaction flask. Isolation of the required enol silane or silyl ketene acetal is not necessary. For example, crossed aldol reactions between α-disubstituted aldehydes and non-enolizable

  三甲基甲硅烷基三氟甲磺酸盐（TMSOTf）和三烷基胺碱可在单个反应瓶中促进原位烯醇硅烷/甲硅烷基烯酮缩醛的形成和Mukaiyama aldol加成反应。不需要分离所需的烯醇硅烷或甲硅烷基烯酮缩醛。例如，α-二取代的醛与不可烯化的醛之间的交叉醇醛缩合反应以良好的产率产生β-羟基醛。在相关的反应中，普通的实验室溶剂乙酸乙酯既充当烯醇化物前体又充当绿色反应溶剂。当使用硫酯作为烯醇化物前体时，常规观察到高产率地加成到不可烯化的醛中。
• Dimethylzinc-Mediated, Oxidatively Promoted Reformatsky Reaction of Ethyl Iodoacetate with Aldehydes and Ketones
  作者：Pier Giorgio Cozzi、Alessandro Mignogna、Paola Vicennati

  DOI：10.1002/adsc.200700572

  日期：2008.5.5

  A practical and general Reformatsky reaction, promoted by oxidants and mediated by dimethylzinc, is described. The reaction is fast and runs at 0 °C with aldehydes and ketones, under mild reaction conditions. Preliminary results obtained for the enantioselective version show that inexpensive chiral amino alcohols could be used in the challenging formation of enantioenriched quaternary stereogenic centers

  描述了一种由氧化剂促进并由二甲基锌介导的实用且通用的Reformatsky反应。该反应快速，可在温和的反应条件下于0°C与醛和酮一起运行。对映体选择性形式获得的初步结果表明，廉价的手性氨基醇可用于富挑战性地形成对映体富集的季立体异构中心。
• P(<i>i</i>-PrNCH₂CH₂)₃N: Efficient Catalyst for Synthesizing β-Hydroxyesters and α,β-Unsaturated Esters using α-Trimethylsilylethylacetate (TMSEA)
  作者：Kuldeep Wadhwa、John G. Verkade

  DOI：10.1021/jo900477q

  日期：2009.6.5

  We present an efficient synthesis of β-hydroxyesters and α,β-unsaturated esters via activation of the silicon−carbon bond of α-trimethylsilylethylacetate using catalytic amounts of the commercially available P(i-PrNCH2CH2)3N 1a. Selectivity for either of these two products can be achieved simply by altering the catalyst loading and reaction temperature to afford addition or stereoselective condensation

  我们提出了通过使用催化量的市售P（i- PrNCH 2 CH 2）3 N 1a活化α-三甲基甲硅烷基乙酸乙酯的硅碳键来有效合成β-羟基酯和α，β-不饱和酯的方法。通过改变催化剂的加入量和反应温度以提供加成或立体选择性缩合，可以简单地实现对这两种产物中任一种的选择性。这种方法比较温和，可以耐受各种各样的官能团。
• Fused pyridine derivatives
  申请人：Eisai Co., Ltd.

  公开号：US06340759B1

  公开（公告）日：2002-01-22

  The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2 represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

  目前提供了一种由以下公式表示的缩合吡啶化合物（I）： （其中，R2代表环A代表苯环、吡啶环、噻吩环或呋喃环；B代表其药学上可接受的盐或其水合物，是一种具有血清素拮抗作用的临床上有用的药物，特别用于治疗、改善或预防痉挛性麻痹或改善肌张力过高的中枢肌肉松弛剂。